PDCD1 and endometrial cancer: In endometrial cancer, considering mismatch repair MMR status, the pooled HR for OS was 0.71 (95% CI: 0.60-0.82; p <.001; Supplementary Figure 2F) in pMMR patients who received PD-1 inhibitors compared to those who did not (24, 25).